0001415889-24-004627.txt : 20240221
0001415889-24-004627.hdr.sgml : 20240221
20240221163205
ACCESSION NUMBER: 0001415889-24-004627
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240216
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dananberg Jamie
CENTRAL INDEX KEY: 0001734424
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39402
FILM NUMBER: 24660167
MAIL ADDRESS:
STREET 1: 3280 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Annexon, Inc.
CENTRAL INDEX KEY: 0001528115
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 275414423
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: (650)-822-5500
MAIL ADDRESS:
STREET 1: 1400 SIERRA POINT PARKWAY
STREET 2: BLDG C, SUITE 200
CITY: BRISBANE
STATE: CA
ZIP: 94005
4
1
form4-02212024_040231.xml
X0508
4
2024-02-16
0001528115
Annexon, Inc.
ANNX
0001734424
Dananberg Jamie
C/O ANNEXON, INC.
1400 SIERRA POINT PKWY, BLDG C, STE 200
BRISBANE
CA
94005
false
true
false
false
CHIEF MEDICAL OFFICER
0
Common Stock
2024-02-16
4
A
0
39000
0
A
39000
D
Stock Option (Right to Buy)
5.13
2024-02-16
4
A
0
160000
0
A
2034-02-16
Common Stock
160000
160000
D
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 16 of each year, with the first 1/3rd vesting on February 16, 2025.
1/48th of the shares subject to the option vest on each monthly anniversary measured from February 16, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
/s/ Jennifer Lew, Attorney-in-Fact
2024-02-21